Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(1)
•••

Comment by GJS471on Feb 09, 2023 2:04pm

159 Views

Post# 35277747

RE:RE:No release date yet for Q4 and Full yr 2022 results

My apologies, you are absolutely correct. I thought there was a date announcing the release of the YE for CPH last year but all I see is the actual release date.

I look forward to the results this year and any information that may come out. I have been very long for a very long time. But the price of entry over time was not bad and it has been one of those stocks that I have believed in and stuck with. Time will tell.
Good luck to all as we see what happens.

<< Previous

Bullboard Posts

Next >>

A leap into the future of tokenized finance